• SB-505124 Hydrochloride: Practical Research Workflows

  2026-09-25

  Use SB-505124 hydrochloride to test how ALK4/5/7-dependent signaling contributes to fibroblast activation, Smad responses, and fibrosis phenotypes. This guide pairs pathway-focused workflows with a clear boundary: the MRTFA–KCNMB1 cancer-stiffness findings motivate complementary assays, but do not establish that this inhibitor regulates cancer-cell mechanics.

• Fasudil (HA-1077) HCl for ROCK Assays

  2026-09-25

  Use Fasudil (HA-1077) HCl to probe ROCK-dependent changes in cell growth, motility, and apoptosis with a workflow built around target engagement and matched controls. The article also shows how recent Hippo-pathway cataract research can inform assay design—without treating that study as evidence that Fasudil protects the lens.

• AZD6482 Workflows for PI3Kβ Signaling

  2026-09-24

  Use AZD6482 to probe PI3Kβ-dependent signaling, metabolic responses, and platelet biology with concentration-aware controls. A DM1 RNA-foci study offers a useful screening-design lesson—but does not show that AZD6482 or PI3Kβ regulates DMPK RNA.

• Beyond Susceptibility: Polymyxin B in Translational Research

  2026-09-24

  Carbapenemase spread makes resistance a moving target. This article connects the membrane-disrupting and immunomodulatory properties of Polymyxin B with practical study design, while clarifying what hospital surveillance data can—and cannot—tell researchers about translational models.

• EdU Imaging Kits (488) for S-Phase Analysis

  2026-09-23

  EdU Imaging Kits (488) use 5-ethynyl-2'-deoxyuridine and click chemistry to label cells synthesizing DNA during S phase. The method supports fluorescence microscopy and flow cytometry without the DNA-denaturation step commonly associated with BrdU detection.

• E-64 in Epithelial Protease Signaling

  2026-09-23

  E-64 is an irreversible L-trans-epoxysuccinyl peptide that enables precise cysteine protease inhibition. This article explains how to use it as a mechanistic perturbation tool alongside cytokine, glucocorticoid, and epithelial signaling assays, with practical guidance for interpreting cathepsin and calpain-dependent effects.

• Hydrocortisone at the Immune–Tumor Interface

  2026-09-22

  A translational strategy for using Hydrocortisone as a glucocorticoid receptor probe across inflammation, barrier biology, neurodegeneration, and immune-evasive kidney cancer research.

• Carbapenemase Gene Transmission in CREC, 2022–2024

  2026-09-22

  A multicenter study of 54 carbapenem-resistant Enterobacter cloacae isolates from eight Guangdong teaching hospitals mapped carbapenemase genes across plasmids and chromosomes while testing their transferability. Its findings highlight the combined importance of blaNDM-1, mobile genetic elements, horizontal gene transfer, and clonal dissemination in hospital-based Gram-negative resistance surveillance.

• Cyanidin Chloride: From Redox to Barrier Biology

  2026-09-21

  Cyanidin Chloride is an anthocyanin polyphenolic antioxidant for linking redox assays with cell-protection and epithelial-barrier research. This identity-aware guide explains how the 2024 psoriasis-model study informs assay design without conflating cyanidin chloride with cyanin chloride.

• GI 254023X: Translational Control of ADAM10

  2026-09-21

  A thought-leadership analysis of GI 254023X as a selective ADAM10 inhibitor, linking sheddase biology, Notch1 signaling, Jurkat-cell assays, endothelial barrier protection, and dose-window strategy for translational research.

• Torin2 and the Next Logic of Cancer Cell Death

  2026-09-20

  Torin2 provides a potent, selective way to interrogate mTOR biology while new Pol II findings encourage researchers to distinguish transcriptional shutdown from active cell-death signaling.

• MK 0893: From Allostery to Translation

  2026-09-19

  A mechanistic and translational analysis of MK 0893 as a reversible glucagon receptor antagonist, connecting allosteric receptor control with cAMP pharmacology, glucose excursion reduction in hGCGR mice, assay design, and type 2 diabetes research strategy.

• VX-702: A State-Aware p38α MAPK Guide

  2026-09-18

  VX-702 is a selective p38α MAPK inhibitor for dissecting inflammatory signaling, but its greatest experimental value emerges when kinase activity and dephosphorylation are measured together. This guide translates recent structural findings into practical assay decisions for cytokine, arthritis, platelet, and cardiac research.

• Angiotensin Peptides and SARS-CoV-2 Spike Binding

  2026-09-18

  The 2025 study identified a structure-dependent ability of naturally occurring angiotensin peptides to enhance SARS-CoV-2 spike-protein binding to host receptors, with the strongest effects associated with shorter peptides and N-terminal deletions. Its findings connect RAAS peptide processing with a potential biochemical determinant of viral receptor engagement, while also defining important limits for interpretation because the work measured binding rather than infection or clinical outcomes.

• Ionizable Drugs for siRNA Co-Delivery

  2026-09-17

  The reference study introduces drug-rich nanoparticles in which an ionizable fulvestrant analog replaces the conventional ionizable lipid used in lipid nanoparticles, enabling co-formulation of a small-molecule drug and siRNA. Its findings show how drug-driven endosomal disruption can support intracellular delivery and reporter-gene knockdown, including cyclin E1 silencing in drug-resistant breast cancer cells.

8109 records 1/541 page Next 12345 下5页 Last page